Bicycle Therapeutics (NASDAQ:BCYC) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Bicycle Therapeutics (NASDAQ:BCYC) released its quarterly earnings results on Thursday. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.04, Briefing.com reports. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The company had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the prior year, the firm posted ($1.26) EPS. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock opened at $22.71 on Friday. The company has a current ratio of 14.77, a quick ratio of 14.77 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $24.19 and its 200-day moving average price is $23.12. The firm has a market cap of $1.08 billion, a P/E ratio of -6.90 and a beta of 0.89. Bicycle Therapeutics has a 12 month low of $12.54 and a 12 month high of $28.67.

Insider Buying and Selling

In other news, CEO Kevin Lee sold 3,212 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 4,584 shares of company stock valued at $102,040 over the last three months. 8.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BCYC shares. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, September 16th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a research note on Friday. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $44.56.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.